Evidence map›Paper›PMID 41890218›Full record

ArticleBiochemistry and biophysics reports2026

Multi-omics analysis reveals AR as a potential prognostic factor and immune-related therapeutic target in gastric cancer.

Tianru Ben, Zonghao Liu, Shitong Cheng, Yanlu Bai, Linlin Gao, Jingya Zhang, Ruixuan Wang, Nan Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianru BenThe First Clinical College of China Medical University, Shenyang, China.
Zonghao LiuThe First Clinical College of China Medical University, Shenyang, China.
Shitong ChengNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Yanlu BaiThe First Clinical College of China Medical University, Shenyang, China.
Linlin GaoNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Jingya ZhangNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Ruixuan WangNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Nan XiaNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although studies have shown that the androgen receptor (AR) is associated with tumor progression and malignant regulation, its role in the tumor immune microenvironment and predictive value for prognosis and immunotherapy response in various cancer types have not been systematically analyzed. Methods: In this paper, multi-omics techniques was used to analyze AR comprehensively. Results: A comprehensive pan-cancer analysis revealed that the AR was expressed in a variety of tumors, especially as a risk factor for poor prognosis in gastric cancer. In addition, gene set enrichment analysis showed that the AR promotes cell proliferation and tumor cell invasion and regulates anti-tumor response. Immune score, immune cell infiltration, and anticancer immune cycle analysis showed that high AR levels were correlated with low infiltration of CD4 Conclusions: In conclusion, this study highlights the potential of the AR as a novel biomarker for gastric cancer prognosis and immunotherapy efficacy, expanding its applicability in the development of new antitumor drugs.

Indexed as

ARGastric cancerImmune infiltrationMulti-omics analysisPan cancerPrognostic signature

Identifiers

PMID41890218
PMCPMC13014673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.